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Abstract
Introduction: In this study, we investigate the efficacy of repairing an osteochondral defect in rabbit knee joints
by administering bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody.
Methods: An osteochondral defect was created on the patellar groove of 20 Japanese white rabbits that were
classified into two recipient groups: group B, administration of bevacizumab (100-mg intravenous injection on the
day of surgery and 2 weeks later), and a control group (defect only). Rabbits were killed 1 and 3 months
postoperatively. Sections were stained with safranin O. Repair sites were evaluated using the modified O’Driscoll
International Cartilage Repair Society grading system. The expression of chondromodulin (ChM)-I and VEGF was
evaluated using immunohistochemical analyses.
Results: At 1 month postoperatively, the repair site in group B was filled with cartilaginous tissue. At 3 months, the
repair site retained this cartilage phenotype. At 1 month in the controls, the defects were mainly filled with fibrous
tissue. At 3 months, the defect was replaced by fibrous tissue and bone. Over the 3-month period, histological
scores were significantly higher in group B than in the controls. At 1 month, group B showed intense positive
results for ChM-I in the bottom of the repair tissue. VEGF was also identified in the same area. In the controls, no
ChM-I was observed in the repair tissue. Conversely, the remodeling hypertrophic chondrocyte layer stained
intensely for VEGF.
Conclusions: Intravenous administration of bevacizumab contributes to better repair of articular cartilage in an
osteochondral defect model. We suggest the possibility of facilitating articular cartilage repair with anti-VEGF
antibody rather than using cultured cells or artificial scaffolds.
Introduction
Mature articular cartilage shows limited capacity for
regeneration after degeneration or injury [1]. For this
reason, various treatments have been developed in
anticipation of restoration by regenerative medicine. At
present, techniques using penetration of subchondral
bone [2-5], microfracture [6-9], mosaicplasty [10-12],
cell transplantation [13-16], and implantation of tissue-
engineered cartilage with various scaffold materials
[17-22] or without scaffold [23-27] have been developed
to overcome this obstacle. Penetration of subchondral
bone such as drilling and microfracture to be filled with
reparative cells from bone marrow is a method that has
been developed to stimulate spontaneous healing [18].
This procedure attempts to achieve repair via the
mechanism of endochondral ossification. However, the
defect to be filled with reparative cells shows a large
amount of vascular invasion, and the tissue tends to be
replaced by bone and a surface of fibrocartilaginous
repair tissue [28].
Successful regeneration of any tissue requires the pre-
sence of reparative cells with the potential to differenti-
ate into the phenotypes required to restore the damaged
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any medium, provided the original work is properly cited.site, but a microenvironment that supports the prolifera-
tion and differentiation of those cells is also needed
[28,29]. In anticipation of favorable articular cartilage
repair in the osteochondral defect model, reparative
cells must be provided with an environment to acquire
the properties of natural articular cartilage. We recently
constructed a 3-D, scaffold-free, tissue-engineered carti-
lage [24] and transplanted this cartilage in only the
superficial layer region of the osteochondral defects as
an initiator of cartilage differentiation in reparative cells
[23] and achieved good restoration effects in the long
term [29]. We confirmed that in the early stage of trans-
plantation, a good restoration effect of articular cartilage
is seen with reparative cells derived from marrow that
acquire antiangiogenic properties [23]. We therefore
hypothesized that good cartilage repair may be achieved
by inhibiting the bioactivity of vascular endothelial
growth factor (VEGF) in the osteochondral defect. A
recent investigation examined the effect of treatment
with anti-VEGF humanized monoclonal antibody (beva-
cizumab), which was developed as a treatment for
malignant tumors [30]. Bevacizumab binds to VEGF
secreted by angiogenic tumors and thereby inhibits
VEGF binding to the VEGF receptor in vascular
endothelial cells, reportedly restraining cancer growth
by inhibiting angiogenesis [31,32].
The objective of this study is to investigate the efficacy
of repair in an osteochondral defect model of the rabbit
knee joint following administration of bevacizumab, a
humanized monoclonal anti-VEGF antibody, without
using cultured cells or artificial scaffolds.
Materials and methods
Animal experiments were approved by the ethics review
board of Tokai University and were performed in accor-
dance with the guidelines on animal use of Tokai
University.
Repair of the osteochondral defect
Twenty Japanese white rabbits (female, 16-18 weeks old,
weighing approximately 3 kg) were used in this study.
The rabbits were anesthetized by exposure to sevoflur-
ane and O2 gas. After receiving a medial parapatellar
incision to both legs, each patella was dislocated laterally
and an osteochondral defect (diameter, 5 mm; depth,
3 mm) was created on the patellar groove of the femur
in both legs using a drill and a biopsy punch (Kai Indus-
tries, Seki, Japan). The bottom of the subchondral bone
w a ss h a v e dt oap l a n eu s i n gt h eb i o p s yp u n c hu n t i l
bleeding was seen from the marrow. Rabbits were classi-
fied into two recipient groups: Group B, with adminis-
tration of bevacizumab (10 rabbits; 100-mg intravenous
injection administered on the day of surgery and 2
weeks later); and controls (10 rabbits; defect only). After
recovery from surgery, all animals were allowed to walk
freely in their cages without any splints.
Histological evaluation of cartilage repair
Rabbits were killed 1 and 3 months postoperatively by
an overdose of intravenous anesthetic. The distal part of
the femur was excised and fixed with 4% paraformalde-
hyde for 7 days. Each specimen was decalcified in a
solution of 10% ethylenediaminetetraacetic acid (EDTA)
in distilled water (pH 7.4) for 2-3 weeks, then embedded
in paraffin wax and sectioned perpendicularly (4.5-m
sections) through the center of the defect. Each section
was stained with safranin O for glycosaminoglycans.
Immunohistochemistry was performed as described
previously [23,33]. Briefly, sections were deparaffinized
according to standard procedures. Sections were treated
with 0.005% proteinase (type XXIV; Sigma-Aldrich Co.,
St. Louis, MO, USA) for 30 min at 37°C for antigen
retrieval. For chondromodulin-I (ChM-I), primary goat
polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) diluted 1:200 in phosphate-buffered sal-
ine (PBS) and 1% bovine serum albumin (BSA) was
placed on the section overnight at 4°C. For VEGF, a pri-
mary mouse monoclonal antibody (Upstate, Lake Placid,
NY, USA) diluted 1:50 in PBS and 1% BSA was placed
on the section overnight at 4°C. Slides were washed
with PBS after incubation for 1 h at room temperature
with biotin-conjugated goat antimouse secondary anti-
body for VEGF and with biotin-conjugated donkey anti-
goat secondary antibody for ChM-I. Next, slides were
treated with horseradish peroxidase-labeled streptavidin
for 1 h and then soaked in 0.05% solution of diamino-
benzidine in Tris HCl buffer (pH 7.6) containing 0.005%
hydrogen peroxide. Finally, slides were counterstained
with Mayer’s hematoxylin. Safranin O-stained sections
were scored by two individuals under blinded condi-
tions, according to a modified O’Driscoll [34] Interna-
tional Cartilage Repair Society (ICRS) grading scale [26]
(Table 1).
Statistical analysis
Results are presented as the means ± standard deviation
(SD). Histological score was analyzed by the Mann-
Whitney U test. Values of P < 0.05 were considered sta-
tistically significant for any differences.
Results
Histological evaluation of repair tissue
Operations were uneventful, and all rabbits immediately
resumed normal cage activity. In Group B, major infec-
tion was identified in one knee at 1 month after surgery
and in three knees at 3 months. These infected knees
were omitted from the study. As a result, nine knees at
1 month and seven knees at 3 months were assessed
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both 1 and 3 months.
At 1 month after surgery, defects in both Group B and
the controls were filled with reparative cells. In Group
B, the repair site appeared to be filled with cartilaginous
tissue, which was stained with safranin O (Figures 1a
and 1b). Lateral integration was well bonded at both
sides of the surrounding cartilage. The surface of the
repair site showed several smooth fibrous cell layers,
and rounded chondrocytes formed inside the repair tis-
sue in a convex pattern. The lower portion of the repair
tissue contained hypertrophic chondrocytes that were
remodeling the subchondral bone. Thus, the defects
showed sequential construction of abundant inhomoge-
neous extracellular matrix from the surface by fibrous
cells (or fibrocartilage cells), rounded chondrocytes and
hypertrophic chondrocytes. Similarly, in the controls,
defects consisted of inhomogeneous extracellular matrix
from fibrous cells (or fibrocartilage cells), rounded chon-
drocytes and hypertrophic chondrocytes; however, no
tendency toward uniform constitution was apparent.
The defect was not filled with repaired tissue (Figures
1 ca n d1 d ) .A t3m o n t h si nG r o u pB ,t h er e p a i rs i t e
maintained a cartilage phenotype and was well inte-
grated with the surrounding cartilage (Figure 2).
Repaired tissue showed a columnar organization. The
surface of the repair site retained a smooth and convex
formation similar to the surrounding cartilage. In the
controls at 3 months, the repair site had been replaced
with fibrous tissue and bone (Figure 3), and in the sur-
rounding adjacent cartilage there was evidence of
osteoarthritic changes with loss of cartilage.
Table 1 Histological grading system
a
Tissue morphology (Ti) Intactness of calcified cartilage layer,
formation of tidemark (Tide)
Lateral integration of implanted material (Latl)
4 = Mostly hyaline cartilage 1 = <25% of the calcified cartilage layer
intact
1 = Not bonded
3 = Mostly fibrocartilage 2 = 25-49% of the calcified cartilage
layer intact
2 = Bonded at one end/partially both ends
2 = Mostly noncartilage 3 = 50-75% of the calcified cartilage
layer intact
3 = Bonded at both sides
1 = Exclusively noncartilage 4 = 76-90% of the calcified cartilage
layer intact
Basal integration of implanted material (Basl)
Matrix staining (Matx) 5 = Complete intactness of the calcified
cartilage layer
1 = <50%
1 = None Subchondral bone formation (Bform) 2 = 50-70%
2 = Slight 1 = No formation 3 = 70-90%
3 = Moderate 2 = Slight 4 = 91-100%
4 = Strong 3 = Strong Inflammation (InfH)
Structural integrity (Stru) Histologic appraisal of surface
architecture (SurfH)
1 = Strong inflammation
1 = Severe disintegration 1 = Severe fibrillation 3 = Slight inflammation
2 = Cysts or disruption 2 = Moderate fibrillation 5 = No inflammation
3 = No organization of
chondrocytes
3 = Slight fibrillation or irregularity Histologic grading system (Hgtot)
4 = Beginning of columnar
organization of chondrocytes
4 = Normal Some of the histologic variables:
5 = Normal, similar to healthy
mature cartilage
Histologic appraisal defect filling (FilH) Tissue morphology (Ti)
Chondrocytes clustering in implant
(Clus)
1 = <25% Matrix staining (Matx)
1 = 25-100% of cells clustered 2 = 26-50% Structural integrity (Stru)
2 = <25% of the cells clustered 3 = 51-75% Cluster formation (Clus)
3 = No clusters 4 = 76-90% Tidemark opening (Tide)
5 = 91-110% Bone formation (Bform)
Histologic surface architecture (SurfH)
Histologic degree of defect filling (FilH)
Lateral integration of defect-filling tissue (Basl) and
histologic signs of inflammation (InfH)
aPresentation of variables and the grading system based on a modified International Cartilage Repair Society (ICRS) grading scale [26] developed by O’Driscoll,
Keeley and Salter [34].
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Page 3 of 10Figure 1 Photomicrographs showing safranin O staining at 1 month after surgery. (a, b) The defect treated with bevacizumab. (c, d) The
defect untreated as the control. Scale bars, 1 mm in (a) and (c) and 250 μm in (b) and (d).
Figure 2 Photomicrographs show safranin O staining at 3 months after surgery. The defect was treated with bevacizumab. Bars, 1 mm in
(a) and 250 μmi n(b, c and d).
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At 1 month, Group B showed intense positive results for
ChM-I at the bottom of the repair tissue in the remo-
deling hypertrophic chondrocyte layer, representing the
border between cartilage and bone (Figure 4a). ChM-I
had accumulated in the interterritorial space of the
repaired matrix (Figure 4a). In the controls, no ChM-I
was observed in the repair tissue (Figure 4b). Conver-
sely, the remodeling hypertrophic chondrocyte layer was
intensely positive for VEGF in both Group B and in the
controls (Figures 4c and 4d).
Histological scoring of repair tissue
We evaluated the repair site using a modified version of
the grading system developed by O’Driscoll, Keeley and
Salter [34]. In this system, 11 histologic categories were
evaluated and scored: tissue morphology (Ti), matrix
staining (Matx), structural integrity (Stru), cluster for-
mation (Clus), tidemark opening (Tide), bone formation
(Bform), histologic appraisal of surface architecture
(SurfH), histologic appraisal of the degree of defect fill-
ing (FilH), lateral integration of defect-filling tissue
(Latl), basal integration of defect-filling tissue (Basl) and
histologic signs of inflammation (InfH). The total score
ranged from 11 (no repair) to 45 (normal articular carti-
lage) (Table 1).
At 1 month, inside the repair tissue in Group B, Ti
was mostly hyaline cartilage in seven of nine cases, with
high cellularity of rounded chondrocytes and mostly
fibrocartilage in two of nine cases. Conversely, in the
controls, 4 of 10 cases showed mostly hyaline cartilage,
4 of 10 cases were mostly fibrocartilage and 2 of 10
cases were mostly noncartilage. For Matx in Group B,
six of nine cases were strong, two of nine cases were
moderate and one case showed slight staining. In the
controls, 5 of 10 cases were strong, 3 of 10 cases were
moderate and 2 of 10 cases showed slight staining. In
Group B, Stru of the defect filling revealed the begin-
ning of columnar organization of chondrocytes in six of
nine cases and no organization of chondrocytes in three
of nine cases. In the controls, 3 of 10 cases showed the
beginning of columnar organization, 4 of 10 cases
showed no organization and 3 of 10 cases showed cysts
or disruptions. In both groups, Clus was not observed
except in one instance. In one instance, there was a
small amount of Clus in both groups. Also, in both
groups, Tide was opened in all instances. In Group B,
subchondral Bform was not recognized in four of nine
cases, slightly recognized in four of nine cases and
strongly recognized in one of nine cases. In the control
group, subchondral Bform was not recognized in 8 of
10 cases and was slightly recognized in 2 of 10 cases.
Figure 3 Photomicrographs show safranin O staining at 3 months after surgery. The untreated defect in the control. Bars, 1 mm in (a) and
250 μmi n(b, c and d).
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Page 5 of 10SurfH in Group B was normal in five of nine cases and
showed slight fibrillation or irregularity in four of nine
cases; in the control group, 1 of 10 cases was normal, 6
of 10 cases showed slight fibrillation or irregularity, 2 of
10 cases showed moderate fibrillation or irregularity and
1 of 10 cases showed severe fibrillation or disruption.
FilH in Group B was complete in six of nine cases and
nearly complete in three of nine cases. In controls, FilH
was complete in 2 of 10 cases, nearly complete in 4 of
10 cases, moderate in 2 of 10 cases and nearly empty in
2 of 10 cases. Latl in Group B was bonded on both
sides in seven of nine cases and bonded at one end or
partially at both ends in two of nine cases. In controls,
Latl was bonded on both sides in 1 of 10 cases, bonded
at one end or partially at both ends in 6 of 10 cases and
not bonded in 3 of 10 cases. Basl was good in all cases
for both groups. In Group B, no inflammation was
observed in all cases for InfH. The control group
showed no inflammation in 5 of 10 cases, slight inflam-
mation in 4 of 10 cases and strong inflammation in 1 of
10 cases. As a result, at 1 month, the total score was sig-
nificantly higher for Group B than for the controls. In
terms of individual scores, SurfH, FilH and Latl for
Group B were significantly higher than in controls.
In Group B, Ti at 3 months showed mostly hyaline
cartilage in six of seven cases. In one of seven cases, tis-
sue was mostly fibrocartilage. Conversely, in the con-
trols, 3 of 10 cases were mostly hyaline cartilage, with
mostly fibrocartilage in 1 of 10 cases and exclusively
noncartilage in 6 of 10 cases. For Matx, six of seven
cases in Group B showed strong staining and one of
seven cases showed moderate staining; in the controls, 3
of 10 cases were strong, one instance was moderate and
6o f1 0c a s e sw e r en o n s t a i n i n g .I nG r o u pB ,S t r uo ft h e
defect filling revealed tissue similar to healthy mature
cartilage in three of seven cases, beginning columnar
organization of chondrocytes in three of seven cases and
no organization of the chondrocytes in one of seven
cases. In the controls, only one instance was similar to
healthy mature cartilage, 2 of 10 cases were beginning
columnar organization, 1 of 10 cases had no organiza-
tion and 6 of 10 cases showed severe disintegration. In
Group B, Clus was not observed. In controls, 2 of 10
cases showed no clusters, 2 of 10 cases showed some
clusters and 6 of 10 cases showed abundant cluster cells
or nonchondrocytes. Tide in Group B was complete in
three of seven cases, nearly complete in two of seven
cases, half degree in one of seven cases and nearly
Figure 4 Chondromodulin (ChM)-I and vascular endothelial growth factor (VEGF) localized in cartilage at 1 month after surgery. (a, c)
The defect treated with bevacizumab. (b, d) The defect in the control. (a) In the bevacizumab group, ChM-I immunostaining is detected in the
interterritorial matrix of the remodeling site. (b) In the control group, ChM-I immunostaining is not detected in the remodeling site. (c, d) In both
groups, VEGF immunostaining is detected in the remodeling site of the reparative cells. Bars, 100 μm in (a) and (b) and 25 μm in (c) and (d).
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Page 6 of 10absent in one of seven cases; in the controls, 1 of 10
cases was complete, 2 of 10 cases were nearly complete,
1 of 10 cases was half degree and 6 of 10 cases were not
recognized as containing a calcified cartilage layer.
Bform was recognized in both groups, except for one
instance in each. In one instance, there was a slightly
Bform in both groups. SurfH in Group B was normal in
five of seven cases and showed slight fibrillation or irre-
gularity in two of seven cases; in the controls, 1 of 10
cases was normal, 1 of 10 cases showed slight fibrillation
or irregularity, 2 of 10 cases showed moderate fibrilla-
tion or irregularity and 6 of 10 cases showed severe
fibrillation or disruption. FilH in Group B was complete
in all instances. In the controls, FilH was complete in 4
of 10 cases, moderate in 1 of 10 cases, nearly empty in
1 of 10 cases and almost empty in 4 of 10 cases. Latl in
Group B were bonded at both sides in six of seven cases
and bonded at one end in one of seven cases. In the
controls, Latl was bonded both sides in 1 of 10 cases,
bonded at one end or partially both ends in 2 of 10
cases and not bonded in 6 of 10 cases. Basl was good in
all cases in both groups. For InfH, no inflammation was
observed in any cases in either group. At 3 months, the
total score for Group B was significantly higher than
that for the controls. In terms of individual scores, Ti,
Matx, Stru, Clus, SurfH, FilH and Latl were significantly
higher for Group B than for the control group (Table 2).
Discussion
VEGF is overexpressed in numerous solid angiogenic
tumors and hematological malignancies. Interrupting
the VEGF pathway has thus become a major focus of
oncology research [35]. The first approved antiangio-
genic therapy was bevacizumab, a humanized
monoclonal anti-VEGF antibody. Following the success
of a pivotal trial, the FDA approved bevacizumab for
use in combination with intravenous 5-fluorouracil-
based chemotherapy as a treatment for patients with
first-line or previously untreated metastatic cancer of
the colon or rectum [36]. Bevacizumab is anticipated to
be useful not only for cancer treatment but also as a
major advance in antiangiogenic therapy.
Generally, osteochondral defects have access to
reparative cells of the bone marrow [37]. This connec-
tion allows infiltration of the bone by mesenchymal
stem cells (MSCs) from the bone marrow, which can
then proliferate and differentiate. MSC-derived chondro-
cytes subsequently appear during endochondral ossifica-
tion and are invaded by the vasculature and marrow,
and eventually the defects are replaced by subchondral
bone [28,38]. In summary, MSC-derived chondrocytes
are spontaneously recruited as reparative cells in osteo-
chondral defects and are replaced by bone with high
levels of vascular invasion. However, articular cartilage
is a naturally avascular tissue, except during skeletal
development, when endochondral bone formation
occurs. We speculate that MSCs may use different
courses of differentiation to become bone or cartilage,
based on environmental differences in vascularization
and avascularization. We recently reported that MSCs
that acquire antiangiogenic properties achieve good car-
tilage restoration [23]. Furthermore, previous research
has shown that VEGF expression by chondrocytes in
osteoarthritic joints may be related to articular cartilage
destruction [39-46]. High-dose VEGF may induce the
onset and progression of arthritis [47,48]. Also, expres-
sion of high levels of VEGF during the terminal stages
of chondrogenesis leads to endochondral ossification
through angiogenesis [49,50]. We therefore studied the
restoration of articular cartilage by blocking VEGF sig-
naling with bevacizumab in a model of osteochondral
defects in Japanese white rabbits.
At 1 month after surgery in both Group B and the
controls, defects were recruited with reparative cells
from the marrow and synovial tissue, and this was com-
posed of differentiated chondrocytes, hyperchondrocytes
and fibrous cells. These heterogeneous cells stained
positive for safranin O and showed various levels of
structured organization. From the surface, these struc-
tures consisted of a fibrous or fibrocartilage layer, a hya-
line cartilage layer and a hypertrophic chondrocyte layer
in both groups. As a result, no significant differences
were apparent between the two groups at 1 month post-
operatively in Ti, Matx or Stru. However, at 1 month
after surgery, the defects were repaired by hyaline carti-
lage (seven of nine cases) in Group B, a result of block-
ing VEGF, whereas in the controls, the defects were
repaired with that of various tissues, including hyaline
Table 2 Histological scores for cartilage repair at 1
month and 3 months after surgery
a
1 month 3 months
Group B Control Group B Control
Ti 3.77 ± 0.4 3.20 ± 0.7 3.85 ± 0.3* 2.10 ± 1.4
Matx 3.55 ± 0.7 3.30 ± 0.8 3.71 ± 0.7* 2.10 ± 1.4
Stru 3.66 ± 0.5 3.00 ± 0.8 4.28 ± 0.7* 2.41 ± 1.6
Clus 2.88 ± 0.3 2.90 ± 0.3 3.00 ± 0.0* 1.60 ± 0.8
Tide 1.00 ± 0.0 1.00 ± 0.0 3.85 ± 1.4 2.20 ± 1.6
Bform 1.66 ± 0.7 1.20 ± 0.4 2.85 ± 0.3 2.90 ± 0.3
SurfH 3.55 ± 0.5* 2.70 ± 0.8 3.71 ± 0.4* 1.70 ± 1.0
FilH 4.66 ± 0.5* 3.70 ± 1.0 5.00 ± 0.0* 2.90 ± 1.9
Latl 2.77 ± 0.4* 1.80 ± 0.6 2.85 ± 0.3* 1.60 ± 0.8
Basl 4.00 ± 0.0 4.00 ± 0.0 4.00 ± 0.0 4.00 ± 0.0
InfH 5.00 ± 0.0 3.80 ± 1.3 5.00 ± 0.0 5.00 ± 0.0
Hgtot 36.55 ± 2.1* 30.50 ± 4.1 40.14 ± 2.5* 27.7 ± 10.0
aValues are means ± SD. The total score range is from 11 (no repair) to 45
(normal articular cartilage).
*Denotes significance at P <0 . 0 5 .
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Page 7 of 10cartilage (4 of 10 cases), fibrocartilage (4 of 10 cases)
and noncartilage (2 of 10 cases). There was no delay in
subchondral bone formation in Group B when blocking
VEGF. For autologous reparative cells, basal integration
was good and most inflammatory signs were absent
from both groups. On the other hand, FilH, Latl and
SurfH were significantly higher for Group B than for the
controls. Actually, at 1 month after surgery, six of nine
cases in Group B showed convex surfaces of these
repaired tissues in surrounding articular cartilage, com-
pared to only 2 of 10 cases in the controls. These results
indicate that blocking VEGF preserves the accumulation
of reparative cells in the defect. This is supported by
studies showing that VEGF treatment prevents conden-
sation of chondrogenic mesenchyme during early limb
bud development through abnormal vascularization [51].
As a sufficient number of reparative cells made contact
with the surrounding cartilage layer, lateral integration
was considered to be good. Also, repaired tissue taking
a convex form consisted of a smoother surface than
repaired tissue with a concave form.
Defects had been repaired by the formation of various
tissues in the controls at 3 months after surgery, which
included hyaline cartilage (3 of 10 cases), fibrocartilage
(1 of 10 cases) and exclusively noncartilage (6 of 10
cases). On the other hand, when blocking VEGF, defects
were repaired mostly with hyaline cartilage (six of seven
cases), with only one case being mostly fibrocartilage.
To emphasize this, no cases showed replacement by
fibrous tissue or bone. Similarly, 1 month after surgery,
the controls showed repair without consistent tissue
morphology, while Group B showed repair with consis-
tency of tissue morphology. At 3 months postopera-
tively, Ti, Matx, Stru and Clus were significantly higher
for Group B than for the controls. In both Group B and
the controls, Tide was generally closed and bone forma-
tion was gradually observed. Continuous basal integra-
tion was also good and most signs of inflammation were
not apparent in either group. Tissue that was repaired
in the form of fibrous tissue and bone tended to show
moderate or severe fibrillation of surface architecture
and low defect filling. Therefore, SurfH and FilH were
significantly higher for Group B than for the controls.
As mentioned before, a sufficient number of reparative
cells were in contact with the surrounding cartilage
layer, and lateral integration was considered to be good.
As a result, at 3 months, the total score was significantly
higher for Group B than for the controls.
Interestingly, ChM-I was expressed in the early stage
of tissue repair after bevacizumab administration. ChM-
I reportedly stimulates chondrocyte proliferation and
proteoglycan synthesis in vitro and inhibits proliferation
of vascular endothelial cells in vitro and in vivo [52,53].
Kitahara et al. [53] suggested that in their mouse model,
ChM-I acts to inhibit vascular invasion in the immature
state of articular cartilage, and levels of ChM-I gradually
decrease with age thereafter. Hiraki et al.[ 5 2 ]r e p o r t e d
that ChM-I is expressed in the avascular zone of carti-
lage in developing bone, but is not present in calcifying
cartilage. Such findings suggest a regulatory role of
ChM-I in vascular invasion during endochondral bone
formation.
In this study, ChM-I was expressed at the bottom of
the repair site invaded near the vasculature. ChM-I
accumulated in the interterritorial space of the repaired
matrix and was surrounding the cells that expressed
VEGF. ChM-I is thought to form a barrier to inhibit
vascular invasion from subchondral bone, indicating
that it facilitates the acquisition of articular cartilage
through the process of MSC differentiation in endo-
chondral ossification. However, the shift from angiogen-
esis to antiangiogenesis is not determined entirely by
ChM-I and VEGF. Inducers of endogenous angiogenic
molecules also exist in the process of endochondral ossi-
fication, and these include VEGF [53], fibroblast growth
factor 2 [54], transforming growth factor [55] and tissue
matrix metalloprotease 9 [56].
In other studies, VEGF has been reported to be neces-
sary for chondrocyte survival during cartilage develop-
ment. In VEGF-deficient mouse models, massive cell
death is observed in the joint and epiphyseal regions of
cartilage during cartilage development [57,58]. In this
study, we blocked VEGF temporarily to initiate repara-
tive cells. To avoid complete inhibition of the bioactivity
of VEGF in reparative cells, we blocked VEGF on the
day of surgery and 2 weeks later. As a result, 1 month
after surgery, reparative cells actually expressed VEGF in
Group B (Figure 4c). Moreover, expression of ChM-I as
an antiangiogenic factor was observed in the layer of
reparative cells involved in blood vessel invasion from
subchondral bone (Figure 4a). It is important to con-
sider the efficacy of various VEGF treatments in the bal-
ance of angiogenesis-antiangiogenesis during
chondrogenic differentiation of MSC-derived reparative
cells. In other words, repair of articular cartilage may be
achievable by adjusting optimal VEGF signaling. In a
recent study, Kubo et al. [39] reported good cartilage
restoration using muscle-derived stem cells that trans-
fected with the genes of Flt-1 (a VEGF antagonist) and
bone morphogenetic protein (BMP) 4 in a mouse osteo-
chondral defect model. However, the techniques applied
in that study were complicated, as they required isola-
tion of stem cells from muscular tissue, gene transduc-
tion and cell culture in vitro, as well as cell
transplantation. Conversely, the present technique
involves the simple means of achieving cartilage restora-
tion by intravenous administration of bevacizumab, a
treatment already cleared for clinical application. Hence,
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Page 8 of 10this method would be applicable in many medical facil-
ities. Thus, vascularization of the tissue environment
after injury or degeneration would be improved to a
more advantageous situation of cartilage repair if VEGF
were blocked. Accordingly, without depending on cells
or tissue transplantation, this approach would augment
the curative effects of existing approaches such as
microfracture or drilling.
The half-life of bevacizumab in the circulation of
humans is reportedly 17-21 days. The approved dose of
bevacizumab in humans is 5 mg/kg, and the clinical
administration interval is more than 2 weeks [30]. Beva-
cizumab is cross-reactive with rabbit VEGF, but has
eightfold lower affinity for rabbit VEGF than for human
VEGF [59]. Therefore, in this study, we investigated
bevacizumab at the dose of 40 mg/kg administered on
the day of surgery and 2 weeks later. As a future con-
sideration, we plan to investigate the dosage and dura-
tion of bevacizumab administration. We will also
address the side effects of infection by applying mini-
mally invasive surgery with an arthroscope and using
antibiotics.
Conclusions
Temporary intravenous administration of the humanized
monoclonal anti-VEGF antibody bevacizumab in an
osteochondral defect model results in positive restora-
tive effects. We suggest that this approach would be
useful to achieve repair of articular cartilage without the
need for cells or tissue transplantation.
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